Next Article in Journal
When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients
Next Article in Special Issue
Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis
Previous Article in Journal
Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells
Previous Article in Special Issue
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels
Open AccessReview

Spinal Cord Involvement in MS and Other Demyelinating Diseases

Neurology Department, Fleni, C1428AQK Buenos Aires, Argentina
*
Author to whom correspondence should be addressed.
Biomedicines 2020, 8(5), 130; https://doi.org/10.3390/biomedicines8050130
Received: 29 April 2020 / Revised: 18 May 2020 / Accepted: 20 May 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Multiple Sclerosis: Diagnosis and Treatment II)
Diagnostic accuracy is poor in demyelinating myelopathies, and therefore a challenge for neurologists in daily practice, mainly because of the multiple underlying pathophysiologic mechanisms involved in each subtype. A systematic diagnostic approach combining data from the clinical setting and presentation with magnetic resonance imaging (MRI) lesion patterns, cerebrospinal fluid (CSF) findings, and autoantibody markers can help to better distinguish between subtypes. In this review, we describe spinal cord involvement, and summarize clinical findings, MRI and diagnostic characteristics, as well as treatment options and prognostic implications in different demyelinating disorders including: multiple sclerosis (MS), neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody-associated disease, and glial fibrillary acidic protein IgG-associated disease. Thorough understanding of individual case etiology is crucial, not only to provide valuable prognostic information on whether the disorder is likely to relapse, but also to make therapeutic decision-making easier and reduce treatment failures which may lead to new relapses and long-term disability. Identifying patients with monophasic disease who may only require acute management, symptomatic treatment, and subsequent rehabilitation, rather than immunosuppression, is also important. View Full-Text
Keywords: myelitis; spinal cord; multiple sclerosis; neuromyelitis optica; acute disseminated encephalomyelitis; myelin oligodendrocyte glycoprotein; glial fibrillary acidic protein myelitis; spinal cord; multiple sclerosis; neuromyelitis optica; acute disseminated encephalomyelitis; myelin oligodendrocyte glycoprotein; glial fibrillary acidic protein
Show Figures

Graphical abstract

MDPI and ACS Style

Marrodan, M.; Gaitán, M.I.; Correale, J. Spinal Cord Involvement in MS and Other Demyelinating Diseases. Biomedicines 2020, 8, 130.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop